Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Jin‐Hyeok Hwang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5643-8461; OpenAlex author ID A5077511979. Sources: ClinicalTrials.gov.

Their work

Papers
67 (first author 1, last author 38)
Trials
3 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
73
Papers, trials and grants by year

2012: 6 papers · 2013: 2 papers · 2014: 1 paper, 1 trial · 2015: 6 papers · 2016: 2 papers, 1 trial · 2017: 6 papers · 2018: 3 papers · 2019: 3 papers · 2020: 10 papers · 2021: 5 papers, 1 trial · 2022: 7 papers · 2023: 2 papers · 2024: 3 papers · 2025: 9 papers · 2026: 2 papers

Papers 50 of 67

  1. Comprehensive clinico-genomic analysis of pancreatic ductal adenocarcinoma: Overcoming biases and limitations. Last author DOI 10.1016/j.canlet.2025.218176↗
  2. Sensitive fiber-optic localized surface plasmon resonance sensor for early pancreatic cancer detection via carbohydrate antigen 19-9 and supplementary biomarke… Co-author DOI 10.1016/j.talanta.2025.129133↗
  3. Development of a serum protein biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma using a machine learning approach. Last author DOI 10.1038/s41598-025-19631-1↗
  4. Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicente… Co-author DOI 10.1093/clinchem/hvaf066↗
  5. Effectiveness and cost analysis of liposomal irinotecan in patients with pancreatic adenocarcinoma: a multicenter real-world study. Co-author DOI 10.1177/17588359251370492↗
  6. Novel mRNA biomarker-based liquid biopsy for the detection of resectable pancreatic cancer. Last author DOI 10.1186/s12885-025-14124-w↗
  7. Spatial transcriptomics reveal high T cell and monocyte status as predictive and prognostic markers in pancreatic cancer. Co-author DOI 10.1186/s12967-025-06599-9↗
  8. Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. Co-author DOI 10.3389/fmicb.2025.1555479↗
  9. Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. Last author DOI 10.4251/wjgo.v17.i2.100167↗
  10. Quantitative immunohistochemistry analysis of pancreatic adenocarcinoma upregulated factor expression in pancreatic cancer and its prognostic significance. Last author DOI 10.4251/wjgo.v17.i9.109055↗
  11. Prognostic Value of the Metabolic Response on Serial 18F-FDG PET/CT in Pancreatic Cancer. Last author DOI 10.5009/gnl240458↗
  12. Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer. Co-author DOI 10.3389/fonc.2024.1510016↗
  13. The Trends and Outcomes of Initial Palliative Chemotherapy in Patients with Pancreatic Cancer in Korea Based on National Health Insurance Service Data. Last author DOI 10.3390/jcm13113229↗
  14. Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. Co-author DOI 10.5009/gnl230303↗
  15. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. Co-author DOI 10.1177/17588359231175441↗
  16. Novel mRNA-based Immunological Biomarker for Early Detection of Resectable Pancreatic Cancer Last author DOI 10.21203/rs.3.rs-2658368/v1↗
  17. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study. Co-author DOI 10.1007/s00330-021-08494-5↗
  18. NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer. Co-author DOI 10.1038/s41598-022-24732-2↗
  19. Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer. Co-author DOI 10.21037/jgo-22-218↗
  20. Downregulation of ASF1B inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer. Last author DOI 10.3233/cbm-210490↗
  21. Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. Last author DOI 10.3389/fonc.2022.1050070↗
  22. Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers14102476↗
  23. Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic C… Last author DOI 10.5009/gnl20312↗
  24. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A bi… Last author DOI 10.1016/j.pan.2021.02.022↗
  25. Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. Last author DOI 10.1038/s41598-021-99647-5↗
  26. Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients. Last author DOI 10.1186/s13104-021-05681-x↗
  27. Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study. Co-author DOI 10.3390/cancers13215466↗
  28. Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. Co-author DOI 10.3390/jpm11020083↗
  29. Reply to the letter to the editor: 'AJCC 8th edition staging system for pancreatic ductal adenocarcinoma: A controversial step forward?' First author DOI 10.1016/j.ejso.2019.10.021↗
  30. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 tria… Last author DOI 10.1016/j.gie.2020.02.012↗
  31. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2020.06.010↗
  32. Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells. Last author DOI 10.1038/s41598-020-73474-6↗
  33. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. Last author DOI 10.1097/coc.0000000000000730↗
  34. Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer. Last author DOI 10.1371/journal.pone.0238649↗
  35. Sex Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX Co-author DOI 10.21203/rs.3.rs-33720/v1↗
  36. Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment. Last author DOI 10.3390/cancers12113137↗
  37. Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. Last author DOI 10.5009/gnl19180↗
  38. Involvement of the NF-κB signaling pathway in proliferation and invasion inhibited by Zwint-1 deficiency in Pancreatic Cancer Cells. Last author DOI 10.7150/jca.46173↗
  39. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejso.2019.06.002↗
  40. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and m… Last author DOI 10.1038/s41598-019-52167-9↗
  41. Non-SMC condensin I complex subunit H mediates mature chromosome condensation and DNA damage in pancreatic cancer cells. Last author DOI 10.1038/s41598-019-54478-3↗
  42. It is necessary to exam bottom and top slide smears of EUS-FNA for pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2018.08.002↗
  43. Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. Last author DOI 10.1097/md.0000000000013592↗
  44. Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis. Last author DOI 10.1136/bmjopen-2017-017249↗
  45. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. Last author DOI 10.1016/j.ejca.2017.02.010↗
  46. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. Last author DOI 10.1016/j.surg.2016.12.038↗
  47. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. Last author DOI 10.1097/md.0000000000005926↗
  48. Prognostic value of p21-activated kinase 4 in resected pancreatic cancer. Co-author DOI 10.1111/apm.12705↗
  49. The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/1010428317718403↗
  50. Early versus delayed initiation of adjuvant treatment for pancreatic cancer. Last author DOI 10.1371/journal.pone.0173960↗

Trials 3

  1. An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy Principal investigator NCT04739046↗
  2. Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients Study chair NCT02862015↗
  3. Effect of Oncothermia on Improvement of Quality of Life in Unresectable Pancreatic Cancer Patients Principal investigator NCT02150135↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaihwan Kim · 43 shared papers, 2015–2026 · strength 6.10
  2. Jong-Chan Lee · 35 shared papers, 2015–2026 · strength 5.64
  3. Kwangrok Jung · 14 shared papers, 2020–2026 · strength 2.91
  4. Yuna Youn · 11 shared papers, 2019–2026 · strength 2.31
  5. Dong Woo Shin · 9 shared papers, 2019–2025 · strength 1.52
  6. Ho‐Seong Han · 14 shared papers, 2012–2025 · strength 1.30
  7. Jae Hyeong Kim · 7 shared papers, 2019–2026 · strength 1.29
  8. Yoo‐Seok Yoon · 13 shared papers, 2012–2025 · strength 1.27
  9. Jinwoo Ahn · 6 shared papers, 2022–2025 · strength 1.27
  10. Yoon Suk Lee · 10 shared papers, 2013–2025 · strength 1.23
  11. Sang Myung Woo · 8 shared papers, 2013–2025 · strength 1.23
  12. Jong-chan Lee · 8 shared papers, 2016–2024 · strength 1.04
  13. Jin Won Kim · 8 shared papers, 2017–2024 · strength 0.96
  14. Jung Won Chun · 4 shared papers, 2024–2025 · strength 0.90
  15. Haeryoung Kim · 9 shared papers, 2012–2022 · strength 0.77
  16. Woo Jin Lee · 5 shared papers, 2019–2025 · strength 0.76
  17. Bo‐Mi Kim · 3 shared papers, 2023–2025 · strength 0.68
  18. Jae Hyup Jung · 4 shared papers, 2020–2024 · strength 0.68
  19. Dong Kee Jang · 3 shared papers, 2024–2025 · strength 0.68
  20. Young Ae Kim · 3 shared papers, 2024–2025 · strength 0.68
  21. Young Hoon Kim · 5 shared papers, 2017–2022 · strength 0.65
  22. Hyoung Woo Kim · 7 shared papers, 2015–2020 · strength 0.65
  23. Soomin Ahn · 3 shared papers, 2020–2025 · strength 0.51
  24. Sang Hyub Lee · 6 shared papers, 2012–2025 · strength 0.42
  25. Dong‐Won Ahn · 3 shared papers, 2012–2025 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.